|
||
| |||||||
|
POWDERMED APPOINTS ADAM CHRISTIE AS CHIEF BUSINESS OFFICER Oxford, UK, 8th November 2004 – PowderMed Ltd (PowderMed), a company focusing on the development of therapeutic DNA vaccines has announced that it has appointed Adam Christie as Chief Business Officer. Mr Christie has strong commercial and business development experience in the life science industry. His most recent position was as Business Development Director of PPL Therapeutics. Previous positions included working for GlaxoSmithKline, ABN Amro, Fisons, Abbott Laboratories and Schering AG. Welcoming Adam as the new Chief Business Development Officer, Clive Dix, CEO of PowderMed commented: “Adam’s wealth of commercial and business development experience will strengthen the Powdermed Executive Team. His experience will be invaluable both for the successful completion of future licensing deals and for PowderMed’s corporate development activities.” Commenting on his appointment, Mr. Christie said: “I am extremely excited at the prospect of contributing to PowderMed becoming the worlds leading therapeutic vaccine company.” -ends- NOTES FOR EDITORS About PowderMed Ltd – www.powdermed.com PowderMed Ltd, based in Oxford, United Kingdom, is a leader in the development of therapeutic DNA Vaccines. The Company was created through a spin-out of the powder injection DNA Vaccines technology from Chiron Vaccines, a business unit of Chiron Corporation (NASDAQ: CHIR). PowderMed has acquired the rights to the PowderJect™ Particle Mediated Epidermal Delivery (PMED™) technology which it plans to use, in the first instance, in the development of therapeutic DNA vaccines targeting chronic viral diseases and cancer. PowderMed has a proprietary therapeutic vaccine for the treatment of genital herpes in Phase I trials and also two partnered Phase I programmes in Cancer (Ludwig Institute) and HIV/AIDS (GlaxoSmithKline). In addition the Company has two proprietary preclinical lead programmes targeting genital warts and, hepatitis B. The Company will seek to further its technology in areas outside of its strategic focus through partnerships and collaborations. Further enquiries: Northbank Communications Ltd Dr Douglas Pretsell or Sue Charles Tel: +44 (0)20 7886 8150 d.pretsell@northbankcommunications.com s.charles@northbankcommunications.com PowderMed Ltd Dr Clive Dix Tel: +44 (0)1865 501 549
|
|
| ||||||||